Melanoma

• Moderna and Merck announced that a personalized mRNA cancer vaccine successfully slowed the recurrence and spread of melanoma in a late-stage clinical trial. • The vaccine was administered in combination with Merck's immunotherapy drug, Keytruda, to enhance the body's immune response against the cancer. • This result is significant as it demonstrates the potential for mRNA technology to be adapted for oncology, moving beyond its success in COVID-19 vaccinations.

• Moderna and Merck announced that a personalized mRNA cancer vaccine, used alongside the immunotherapy drug Keytruda, successfully reduced the risk of recurrence and spread of melanoma in a late-stage trial. • The positive interim analysis caused Moderna’s shares to surge by as much as 160 per cent on Wednesday. • This development marks a significant milestone in the emerging field of personalized cancer treatment, potentially benefiting thousands of high-risk patients who have undergone tumor removal surgery.

• Merck and Moderna announced that their personalized mRNA vaccine successfully met its goals in a late-stage trial by preventing skin cancer from returning in high-risk melanoma patients. • While the results have been met with enthusiasm from observers, the companies have not yet released the full data from the ongoing study. • This development marks a significant step in applying mRNA technology to oncology, following Moderna's recent FDA approval for an mRNA flu shot.

• Merck and Moderna announced that an experimental cancer vaccine-drug combination shows promise in preventing the recurrence of melanoma in high-risk patients. • While full trial data has not yet been published, previous research presented in June at the American Society of Clinical Oncology meeting indicated the treatment halved the risk of recurrence over five years for 157 patients. • This development is significant as it suggests a potential breakthrough in long-term cancer survival and the prevention of relapse for high-risk individuals.

• Merck and Moderna announced that their Phase 3 INTerpath-001 trial met primary endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with completely resected stage IIB-IV melanoma. • The study found that combining KEYTRUDA with intismeran autogene—an mRNA-based individualized neoantigen therapy tailored to a patient's specific tumor mutations—provided statistically significant improvements over using KEYTRUDA alone. • This marks the first and only combination regimen to demonstrate such clinically meaningful improvements in the adjuvant melanoma setting.

• The FDA has approved a new engineered viral immunotherapy designed specifically for patients suffering from treatment-resistant advanced melanoma. • This approval provides a critical new therapeutic option for cancer patients who have failed to respond to existing standard-of-care treatments. • The authorization is granted under conditions where continued market availability may be contingent upon the verification of clinical benefits.

• The FDA has approved Replimune’s treatment for advanced melanoma, marking a significant victory for the company and patient advocates. • The drug's approval follows a tumultuous process in which it was previously rejected by the agency twice before clearing an advisory committee last week. • This decision provides a critical new therapeutic option for patients suffering from advanced stages of skin cancer.